GlaxoSmithKline Total Current Liabilities from 2010 to 2024

GSK Stock   1,340  3.50  0.26%   
GlaxoSmithKline PLC's Total Current Liabilities is increasing over the years with slightly volatile fluctuation. Total Current Liabilities is expected to dwindle to about 11.2 B. Total Current Liabilities is the total amount of liabilities that GlaxoSmithKline PLC is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations. View All Fundamentals
 
Total Current Liabilities  
First Reported
1986-06-30
Previous Quarter
20.3 B
Current Value
21.5 B
Quarterly Volatility
7.5 B
 
Black Monday
 
Oil Shock
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check GlaxoSmithKline PLC financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among GlaxoSmithKline PLC's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.2 B, Interest Expense of 502.2 M or Total Revenue of 19.9 B, as well as many indicators such as . GlaxoSmithKline financial statements analysis is a perfect complement when working with GlaxoSmithKline PLC Valuation or Volatility modules.
  
This module can also supplement various GlaxoSmithKline PLC Technical models . Check out the analysis of GlaxoSmithKline PLC Correlation against competitors.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Other Information on Investing in GlaxoSmithKline Stock

GlaxoSmithKline PLC financial ratios help investors to determine whether GlaxoSmithKline Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in GlaxoSmithKline with respect to the benefits of owning GlaxoSmithKline PLC security.